2015 starts in early November for IDRA, and it will be an enormous year for this company. Look at what they have accomplished in the last year. This year we get WM data and MAJOR AUTOIMMUNE indications x2 for 9200. I'm thinking Lupus for sure, and possibly Arthritis for the second. Then we get full WM, DLBCL, GvHD, and PM/DM, data --- all in the next 10 months. Also, and this is a very big also, GSO indications 1H2015 with clinical launch --- no toxicity, better delivery. The Phase 2's will generate Accelerated Approval development due to the rarity of these diseases. You get ONE SHOT at a run for this kind of company, and you're either in or out when it happens. Could happen in December at ASH with astounding WM results. Could happen at ASCO with DLBCL results. Could happen with GSO. I think their gene-targeting results with WM and DLBCL will tell the story of where this company is headed, who is runnig it, and just how solid their foundation is.
"End of the year will be exciting heading into 2015. "These clinical-stage candidates have demonstrated activity in multiple preclinical models of autoimmune disease and cancer, including psoriasis, lupus, arthritis, and MYD88 L265P-positive B-cell lymphoma. In addition, the company plans to finalize a strategic assessment of potential indications for further clinical development of IMO-9200 by year end." I fully expect Lupus and Arthritis to be the first two 9200 indications. Buy and hold this baby for long-term 10x-20x your money. Best rheumatologists in the world are on IDRA's Clinical Board of Advisors. That's no accident. My price targets are 20s 2015, 40s 2016-2017. Do your own DD. I have. Geraghty has. Bakers Have. Fidelity has. Blackrock has.
You got it, Mikey. IDRA has had her crash and is starting her ascent. Selling out of fear at these levels would be regrettable. Million-share buy yesterday and another 700k on the bid today. Not enough sellers. MM will have to take it up sometime. Then people will chase to 8.50.
Next month or December ASH. What data will they present? Likely, the ones with most astounding benefit from treatment. That's why we are seeing enormous bids yesterday, today, and into the EOY. Patience will be rewarded.
In addition, data from a well-characterized preclinical model of lupus showed that IMO-9200 improved disease-associated parameters in MRL/lpr mice, with decreases in blood urea nitrogen levels, proteinuria, autoantibodies and kidney interstitial inflammation. Idera has evaluated IMO-9200 in additional autoimmune disease models, and plans to present data from these studies in the future.
"The findings announced today provide further support for our proprietary TLR antagonism technology by demonstrating the specific and potent inhibitory activity of IMO-9200 against TLRs that have been implicated in multiple autoimmune diseases," said Sudhir Agrawal, D. Phil., Chief Executive Officer of Idera Pharmaceuticals. "While we continue to advance our lead TLR antagonist candidate IMO-8400 in ongoing and planned clinical trials in genetically defined forms of B-cell lymphoma and rare autoimmune diseases, we believe that the expansion of our clinical-stage pipeline with IMO-9200 may allow us to address an even broader range of autoimmune and inflammatory disorders in which TLRs have been shown to be over-activated."
Idera plans to begin dosing of IMO-9200 in a Phase 1 clinical trial in healthy volunteers in the fourth quarter. In addition, the company plans to finalize a strategic assessment of potential indications for further clinical development of IMO-9200 by year end.
No chance on BK. Would never get approved with assets approaching 10bill and revs in billions. Company already announced deal will be done in interests of shareholders.
Company has already announced financing will be done on better terms. Ladder down for a 2-point bounce on done deal. Douche Bank making serious coin off their fear injection. Buy that fear alongside the crooks.
Sentiment: Strong Buy
Not necessarily. It's very targeted. Cold be mindblowing news like patients with shrunken tumors, patients in remission, WM stopped in its tracks. That is what the pre-clinical results have produced and THAT is what will move the stock significantly. And if it does do that, it means it is successfully targeting a gene that is found multiple B-cell lymphomas. This 9200 news was bland at best. It's the WM/DLBCL results that start rolling out from November to ASH to ASCO that will define the company's success and stock price. 9200 with a partner and lupus/psoriasis will come later apparently.